Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 30.88.
Forward PE Ratio (30.88) = Close Price ($1128.32) / Consensus Forward EPS ($36.39)
FORWARD PE RATIO
30.88
SECTOR MEDIAN · HEALTHCARE
19.84
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
+55.68%
vs the sector median at left
Eli Lilly and Company
Market Cap
$1.06T
Forward PE Ratio
30.88
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Eli Lilly and Company (LLY) | $1.06T | 30.88 |
| Johnson & Johnson (JNJ)vs › | $647.80B | 23.23 |
| AbbVie Inc. (ABBV)vs › | $441.18B | 17.74 |
| Merck & Co., Inc. (MRK)vs › | $364.36B | 54.00 |
| UnitedHealth Group Incorporated (UNH)vs › | $354.70B | 20.29 |
| Roche Holding AG (RHHBY)vs › | $342.57B | 22.08 |
| AstraZeneca PLC (AZN)vs › | $245.15B | 15.63 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $225.75B | 24.01 |
| Amgen Inc. (AMGN)vs › | $212.27B | 17.04 |
| Novo Nordisk A/S (NVO)vs › | $199.51B | N/A |
Trailing P/E
37.7
reported TTM EPS
Forward P/E
30.9
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $36.39 implies +22.1% EPS growth vs the reported trailing $29.80.
At today's $1128.32 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $36.39 | $32.95 – $39.14 | 15 | 31.0x |
| 2027-12-31 | $46.64 | $41.02 – $51.78 | 15 | 24.2x |
| 2028-12-31 | $53.49 | $48.07 – $59.46 | 9 | 21.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
